CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without ECM (CorMatrix)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01535807

Recruitment Status : Terminated

First Posted : February 20, 2012

Results First Posted : December 24, 2015

Last Update Posted : January 11, 2022

Sponsor:

Collaborator:

CorMatrix Cardiovascular, Inc.

Information provided by (Responsible Party):

Inova Health Care Services

Study Description

Brief Summary:

The objective of this study is to identify proteomic inflammatory biomarkers to determine if there are differences in the biomarkers in patients who are treated using the CorMatrix ECM implant to close the pericardium and the patients whose pericardium is left open (the current standard of care).

Condition or disease	Intervention/treatment	Phase
Coronary Artery Disease	Device: CorMatrix extra cellular matrix (ECM)	Not Applicable

Show detailed description

Detailed Description:

The pericardium's main function is to secrete proteins that ensure proper functioning within the pericardial space and to maintain pericardial pressure. Once dissected the pericardium is usually left open at the end of surgery due to the difficulty in realigning the edges and to avoid adverse effects cause by an inflammatory response. The body's inflammatory response is one of protection and healing of an injury. However many of the inflammatory biomarkers released can cause adverse outcomes after cardiac surgery, including: renal failure, myocardial infarction, atrial fibrillation, stroke and death.

CorMatrix extra cellular matrix (ECM) Technology is a Food and Drug Administration (FDA) approved unique extra cellular implant material used for pericardial closure and reconstruction. Pericardial reconstruction using porcine intestinal ECM is a novel application. ECM combines the innate attributes of nature with the precision of science to help the heart heal itself. It is an acellular biomaterial that does not encapsulate when surgically implanted, but is gradually remodeled, leaving behind organized and healthy tissue. The body's tissue begins remodeling at the surgical site while the ECM maintains the needed tissue support. When implanted, the ECM acts as a scaffold into which the patient's cells migrate and integrate, stimulating the patient's natural wound-healing mechanisms. As the patient's cells become active, they lay down their own collagen, which matures over time to form strong and permanent tissue repair without leaving behind permanent foreign material. Because the ECM contains primarily collagen, the device is gradually replaced as the patient's tissue gradually turns over in a natural state of self-renewal.

A retrospective study compared the incidence of post operative atrial fibrillation (POAF) in patients treated with the CorMatrix ECM for pericardial closure following isolated coronary artery bypass graft (CABG) versus patients not treated with the patch. The retrospective study comprised of 222 patients. 111 were treated with the CorMatrix ECM and the other 111 were not. Results showed POAF in 34 of 111 control patients but only 20 in 111 CorMatrix ECM treated patients, indicating a 54% decrease in the risk of POAF in the CorMatrix ECM treated patients. This study shows a statistically significant reduction in the risk of POAF in patients undergoing an isolated CABG with pericardial closure using the CorMatrix ECM.

This is an unblinded, randomized study to identify proteomic inflammatory biomarkers to determine if there are differences in the biomarkers in patients who are treated using the CorMatrix ECM implant to close the pericardium and the patients whose pericardium is left open (the current standard of care). The study will be located at the Inova Heart and Vascular Institute (IHVI). The CorMatrix ECM will be implanted during the CABG surgical procedure in the IHVI cardiovascular operating rooms (CVOR).

Sixty (60) patients who are routinely scheduled for a CABG will be recruited and randomly assigned to one of the two groups. There will be thirty (30) patients in each group. The control "No Intervention" group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care. The treatment "Cormatrix" group will receive the CorMatrix EMC during surgery for the closure of the pericardium according to the specific recommended surgical technique.

Pericardial fluid and blood samples will be collected from all patients. Pericardial fluid and blood samples will undergo novel nanoparticle based biomarker discovery technology to harvest proteomic biomarkers at the George mason University. In addition, patients will have their cardiac rhythm continually assessed during their hospital stay and then at their follow up appointments with their surgeon and cardiologist to determine whether they developed POAF post discharge.

Both genders, greater than eighteen (18) years of age, will be included in the research. There are no enrollment restrictions based upon race or ethnic origin and it is expected their inclusion will be representative of the population undergoing CABG at IHVI. Pregnant women are excluded from the study.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	44 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without CorMatrix's Extra Cellular Matrix (ECM)
Actual Study Start Date :	January 2012
Actual Primary Completion Date :	February 2013
Actual Study Completion Date :	June 2016

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: CorMatrix Group The treatment "Cormatrix" group will receive the CorMatrix EMC during surgery for the closure of the pericardium according to the specific recommended surgical technique.	Device: CorMatrix extra cellular matrix (ECM) Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique. No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care. Other Name: CorMatrix ECM, CorMatrix, ECM
No Intervention: Control The control "No Intervention" group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care.

Outcome Measures

Primary Outcome Measures :

Inflammatory Biomarkers [ Time Frame: Blood and Pericardial Fluid Baseline draw. Pericardial Fluid Post-Op Draw. Blood Post-Op draw Day 1 and Day 3. ]
- The identification of global low molecular weight (LMW) serum proteomic changes associated with CorMatrix ECM treated patients.
- Identification of porcine specific LMW and phosphoproteomic serum protein changes associated with CorMatrix ECM treated patients.

Secondary Outcome Measures :

Post Operative Atrial Fibrillation [ Time Frame: Within 30 days ]
Post operative rhythm during hospital stay. Rhythm on discharge. Rhythm at cardiac surgery visit. Rhythm within 30 days of surgery.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subject is ≥18 years of age
Subject must be selected as a candidate for isolated Coronary Artery Bypass Graft (CABG) procedure
Subject has a Left Ventricular Ejection Fraction (LVEF) of ≥30%
Subject is able and willing to provide written informed consent and HIPAA authorization
Subject has a life expectancy of at least one year

Exclusion Criteria:

Subject is scheduled for other concomitant surgical procedures (carotid surgery included)
Subject has a known hypersensitivity to porcine material
Subject has a religious or cultural objection to the use of blood or porcine products
Subject is scheduled for Off Pump Coronary Artery Bypass procedures (OPCAB)
Subject has a history of diagnosed treated or un-treated pre-operative atrial fibrillation or any other type of cardiac arrhythmia
Subject has a history of anti-arrhythmic drug treatment in the past six (6) months
Subject has an implantable cardiac device (e.g., pacemakers, implantable cardioverter defibrillators)
Subject has a history of an accessory pathway disorder (e.g., Wolff-Parkinson-White syndrome)
Subject has a documented myocardial infarction (MI) within six (6) weeks prior to study enrollment
Subject needs emergent cardiac surgery (i.e., cardiogenic shock)
Subject requires intra-aortic balloon pump or intravenous inotropes
Subject has had an infection within six (6) weeks preceding surgery requiring antibiotic therapy
Subject is on pre-surgical immunosuppressive therapy (corticosteroids included)
Subject has chronic inflammatory disease (leukemia, lymphoma, arthritis, rheumatoid, lupus, Crohn's disease, ulcerative colitis, hepatitis C, HIV)
Subject has had therapeutic radiation to the pericardium, either prior to surgery or expected during the three (3) week period following surgery
There is an inability to approximate the graft and pericardium edge along the entire extent of the defect
Subject is incarcerated
Subject is participating in concomitant research studies of investigational products (e.g., Appendage closure devices, septal defect patches)
Subject is unable to provide informed consent

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01535807

Locations

Layout table for location information

United States, Virginia
Inova Heart and Vascular Institute
Falls Church, Virginia, United States, 22042

Sponsors and Collaborators

Inova Health Care Services

CorMatrix Cardiovascular, Inc.

Investigators

Layout table for investigator information

Principal Investigator:	Niv Ad, MD	Inova Health Systems

More Information

Additional Information:

ECM Technologies by CorMatrix This link exits the ClinicalTrials.gov site

Layout table for additonal information

Responsible Party:	Inova Health Care Services
ClinicalTrials.gov Identifier:	NCT01535807
Other Study ID Numbers:	CorMatrix ECM Study
First Posted:	February 20, 2012 Key Record Dates
Results First Posted:	December 24, 2015
Last Update Posted:	January 11, 2022
Last Verified:	December 2021

Keywords provided by Inova Health Care Services:


Atrial Fibrillation Cardiac surgery Coronary Artery Bypass Graft CorMatrix extra cellular matrix	Heart surgery Inflammatory Biomarkers Myocardial Infarction identify proteomic inflammatory biomarkers

Additional relevant MeSH terms:

Layout table for MeSH terms

Coronary Artery Disease Coronary Disease Myocardial Ischemia Heart Diseases	Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases

To Top